← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Vaxnewmo, Llc
Saint Louis, MO
$11,175,048
Total funding
8
Grants
Funding over time
peak $3M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,175,048 · 8
By mechanism
R44$6,900,317 · 3
R42$2,591,387 · 1
R41$1,683,344 · 4
Investigators at Vaxnewmo, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections$1,000,000
R44 · FY2025 · AI
Development of a Group B Streptococcus bioconjugate vaccine$1,000,000
R44 · FY2023 · AI
A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections$999,717
R42 · FY2025 · AI
Development of a Group B Streptococcus bioconjugate vaccine$995,682
R44 · FY2024 · AI
Development of a Group B Streptococcus bioconjugate vaccine$995,682
R44 · FY2025 · AI
A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections$994,178
R42 · FY2024 · AI
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines$992,959
R44 · FY2021 · AI
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines$984,934
R44 · FY2022 · AI
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines$931,060
R44 · FY2020 · AI
A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections$300,000
R41 · FY2022 · AI
Development of a bioconjugate vaccine against Group B Streptococcus$300,000
R41 · FY2019 · AI
Glycoengineering a bioconjugate vaccine against Klebsiella pneumoniae$299,999
R41 · FY2018 · AI
A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections$299,238
R42 · FY2022 · AI
A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections$298,254
R42 · FY2023 · AI
A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections$293,112
R41 · FY2023 · AI
Development of a bioconjugate vaccine against Group B Streptococcus$280,104
R41 · FY2020 · AI
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines$210,129
R41 · FY2017 · AI